Biological drugs prescription issues in terms of the new coronaviral infection COVID-19 pandemic. Literature review and clinical case

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


BACKGROUND: The spread of the novel coronaviral infection has set important medical society goals, such as the development of effective treatment and preventive modalities (including biologic agents) for COVID-19. Moreover, during this pandemic, the management of chronically ill patients that require immunosuppressive therapy is also a matter of great concern. Analysis of currently obtained data has concluded that patients treated with biologic agents have no elevated risk for COVID-19. Leading medical societies give an opinion in their clinical guidelines that management with biologic drugs should be continued during the COVID-19 pandemic. The feasibility of initiating treatment with a biologic agent depends on the risk-benefit ratio for the drug, the assessment of possible complications along with the associated risks for a poor outcome because of an underlying disease.

CASE REPORT: We present a case report of a patient with erythrodermic psoriasis and psoriatic arthritis treated with ixekizumab during COVID-19 quarantine.


Full Text

Restricted Access

About the authors

L. S. Kruglova

Federal State Institution of Additional Postgraduate Education “Central State Medical Academy” Department for Presidential Affairs of the Russian Federation

Email: dr.polonskaia@gmail.com
ORCID iD: 0000-0002-5044-5265

Russian Federation, Moscow

E. A. Shatokhina

Federal State Institution of Additional Postgraduate Education “Central State Medical Academy” Department for Presidential Affairs of the Russian Federation

Email: dr.polonskaia@gmail.com
ORCID iD: 0000-0002-0238-6563

Russian Federation, Moscow

Alexandra S. Polonskaya

Federal State Institution of Additional Postgraduate Education “Central State Medical Academy” Department for Presidential Affairs of the Russian Federation

Author for correspondence.
Email: dr.polonskaia@gmail.com
ORCID iD: 0000-0001-6888-4760

Russian Federation, Moscow

MD

References

  1. Kruglova LS, Pereverzina NO, Shatokhina EA. Questions of the use of genetically engineered drugs in the context of the new coronavirus infection COVID-19. Kremlin Medicine. Clinical Bulletin. Russian Journal. 2020;(2):36-43. (in Russian)
  2. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827. doi: 10.3389/fimmu.2020.00827.
  3. Lau S, Lau C, Chan K, Li C, Chen H, Jin D, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol. 2013;94(12):2679-90. doi: 10.1099/vir.0.055533-0.
  4. Channappanavar R, Fehr A, Vijay R, Mack M, Zhao J, Meyerholz D, Perlman S. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181-93. doi: 10.1016/j.chom.2016.01.007.
  5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
  6. Yang Y, Shen C, Li J, Yuan J, Yang M, Wang F, et al. Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. MedRxiv. 2020. doi: 10.1101/2020.03.02.20029975. Available at: https://www.researchgate.net/publication/339762849_Exuberant_elevation_of_IP-10_MCP-3_and_IL-1ra_during_SARS-CoV-2_infection_is_associated_with_disease_severity_and_fatal_outcome
  7. Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(0):E005. doi: 10.3760/cma.j.issn.1001-0939.2020.0005.
  8. Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, Manson J. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 10.1016/S0140-6736(20)30628-0.
  9. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607-13. doi: 10.1016/j.jinf.2020.03.037.
  10. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970-5. doi: 10.1073/pnas.2005615117.
  11. Roumier M, Paule R, Vallee A, Ackermann F. Interleukin-6 blockade for severe COVID-19. MedRxiv. 2020. doi: 10.1101/2020.04.20.20061861.
  12. Qiu P, Cui X, Sun J, Welsh J, Natanson C, Eichacker P. Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. Crit Care Med. 2013; 41(10):2419-29. doi: 10.1097/CCM.0b013e3182982add.
  13. McDermott J, Mitchell H, Gralinski L, Eisfeld A, Josset L, Bankhead A, et al. The effect of inhibition of PP1 and TNFα signaling on pathogenesis of SARS coronavirus. BMC Syst Biol. 2016;10(1):93. doi: 10.1186/s12918-016-0336-6.
  14. Taylor P, Peters A, Paleolog E, Chapman P, Elliott M, McCloskey R, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000;43(1):38-47.
  15. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):761-70. doi: 10.1080/22221751.2020.1747363.
  16. Shakoory B, Carcillo J, Chatham W, Amdur R, Zhao H, Dinarello C, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275-81. doi: 10.1097/CCM.0000000000001402.
  17. Lokugamage K, Hage A, Schindewolf C, Rajsbaum R, Mena-chery V. SARS-CoV-2 is sensitive to type I interferon pretreatment. BioRxiv. 2020. doi: 10.1101/2020.03.07.982264.
  18. Siddiqi H, Mehra M. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405-7. doi: 10.1016/j.healun.2020.03.012.
  19. Shen K, Yang Y. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J Pediatr. 2020;16(3):219-21. doi: 10.1007/s12519-020-00344-6.
  20. Sallard E, Lescure F, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791. doi: 10.1016/j.antiviral.2020.104791.
  21. Huang K, Su I, Theron M, Wu Y, Lai S, Liu C, Lei H. An interferon- gamma-related cytokine storm in SARS patients. J Med Virol. 2005;75(2):185-94. doi: 10.1002/jmv.20255.
  22. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv. 2020. doi: 10.1101/2020.02.10.20021832.
  23. Lagunas-Rangel F, Chavez-Valencia V. High IL-6/IFNγ ratio could be associated with severe disease in COVID-19 patients. J Med Virol. 2020;10.1002/jmv.25900. doi: 10.1002/jmv.25900.
  24. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567. doi: 10.1016/j.autrev.2020.102567.
  25. Arabi Y, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, et al. Ribavirin and interferon therapy for critically Ill patients with middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis. 2020;70(9):1837-44. doi: 10.1093/cid/ciz544.
  26. Zumla A, Chan J, Azhar E, Hui D, Yuen KY. Coronaviruses – drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-47. doi: 10.1038/nrd.2015.37.
  27. Feldmann M, Maini R, Woody J, Holgate S, Winter G, Rowland M, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234):1407-9. doi: 10.1016/S0140-6736(20)30858-8.
  28. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81. doi: 10.1016/S2213-2600(20)30079-5.
  29. Augustin M, von Kiedrowsky R, Korber A, Mrowietz U, Reich K, Thaci D. Recommendations for systemic therapy in persons with psoriasis during the pandemic phase of SARS-COV-2 (corona virus). Available at: https://www.psobest.de/wp-content/uploads/2020/03/RundschreibenPsoBestPsoNetCoronafinalengl.1.1.pdf
  30. European Commission. Novel coronavirus 2019-nCoV. Available at: https://ec.europa.eu/health/coronavirus_en.
  31. FDA. Novel coronavirus (2019-nCoV). Available at: https://www.fda.gov/emergency-preparedness-and response/mcm-issues/novel-coronavirus-2019-ncov.
  32. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020;395(10228):e52. doi: 10.1016/S0140-6736(20)30558-4.
  33. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. International Journal of Infectious Diseases. 2020;94:91-95. doi: 10.1016/j.ijid.2020.03.017.
  34. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8.
  35. Hruza G, Grant-Kels J, Van Beek, Usher E, Thiers BH, Taylor S, et al. Guidance on the use of biologic agents during COVID-19 outbreak, AAD. Available at: https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/023ce3cf6eb82cb304b4ad4a8ef50d56/Biologics_and_COVID-19.pdf
  36. Schwartz RA, Pradhan S, Murrell DF, Jafferany M, Olisova OYu, Lomonosov KM, Lotti T, Goldust M. COVID-19 and immunosupressive therapy in dermatology Dermatol Ther. 2020;e14140. doi: 10.1111/dth.14140.

Supplementary files

Supplementary Files Action
1.
Fig. 1. Dynamics of clinical manifestations of psoriasis in patient A. during treatment with a genetically engineered biological drug ixekizumab (TALS).

Download (945KB) Indexing metadata
2.
Fig. 2. Dynamics of psoriasis severity indices during the course of therapy with ixekizumab in patient A.

Download (181KB) Indexing metadata

Statistics

Views

Abstract - 31

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2020 Kruglova L.S., Shatokhina E.A., Polonskaya A.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies